Retroviral Proteases: Structure, Function and Inhibition from a Non-Anticipated Viral Enzyme to the Target of a Most Promising HIV Therapy

Biological Chemistry Hoppe-Seyler

Volumn 377, Issue 12, 1996, Pages 765-774

  Von Der Helm, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; GAG PROTEIN; INTEGRASE; PEPSIN A; PROTEINASE; PROTEINASE INHIBITOR; RENIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS PROTEIN; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG RESISTANCE; DRUG SOLUBILITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; T LYMPHOCYTE; VIRION; VIRUS CAPSID; VIRUS PARTICLE;

EID: 0030444391     PISSN: 01773593     EISSN: None     Source Type: Journal    
DOI: 10.1515/bchm3.1996.377.12.765     Document Type: Article

References (98)

1. Argos, P., Kamer, G., Nickiin, M. J., and Wimmer, E. (1984). Similarity in gene organisation and homology between proteins of animal picornaviruses and a plant comovirus suggest common ancestry of these virus families. Nucleic Acid Res? 12, 7251–7276.
2. Aliperti, G., and Schlesinger, M. J. (1978). Evidence for an autoprotease activity of sindbis virus capsid protein. Virology 90, 366–369.
3. Barré-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vézinet-Brun, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. (1983). Isolation of aT-lymphotropic retrovirus from a patient at risk for aquired immune deficiency syndrome (AIDS). Science 220,868–971.
4. Bazan and Fletterich (1989). Comperative analysis of viral cysteine protease structural models. FEBS Letters 249,5–7.
5. Brennan, T. M., Taylor, D. L., Bridges, C. G., Leyda, J. R., and Tyms, A. S. (1995). The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res. 26,173–187.
6. Cameron, P. U., Freudenthal, P. S., Barker, J. M., Gezelter, S., Inaba, K., and steinman, R. M. (1992). Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 257,383–387.
7. Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K., and Lin, J. H. (1996). Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24,307–314.
8. Chou, K. C., Tomasselli, A. G., Reardon, I. M., and Heinrikson, R. L. (1996). Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Proteins 24,51–72.
9. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374,569–571.
10. Craig, J. C., Duncan, B., Hockley, D.T. Grief, C., Roberts, N. A., and Mills, J.S. (1991). Antiviral properties of Ro 31–8959, an inhibitor of human immunodeficiency virus (HIV) protease. Antiviral Res. 76,295–305.
11. Craig, J. C., Grief, C., Mills, J., Hockley, D., Duncan, I. B., and Roberts, N. A. (1992), Effects of a specific inhibitor of HIV protease (Ro 31–8959) on virus maturation in a chronically infected promonocytic cell line (U1). Antiviral Chemistry & Chemotherapy 2,181–186.
12. Craig, J. C., Whittaker, L., Duncan, I. B. and Roberts, N. (1994). In vitro anti-HIV and cytotoxicological evaluation of the triple combination AZT and ddC with HIV protease inhibitor saquinavir (Ro-31–8959). Antiviral Chemistry & Chemotherapy 5, 380–386.
13. Debouck, C. (1992), The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses., 153–164.
14. Debouck, C. (1992). Substrate specificity of the human (type I) and simian immunodeficiency virus proteases. In: structure and Function of the Aspartic Proteinases: Genetics, structure, Mechanisms. B. Dunn ed. (New York: Plenum Publishing), pp. 407–415.
15. De Clercq, E. (1995). Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38,2491–2516.
16. Dittmar, K. J., and Moelling, K. (1978). Biochemical properties of p15-associated protease in a avian RNA tumor virus. J. Virol. 28,106–118.
17. Dreyer, G. B., Metcalf, B.W., Tomaszek, T. A., Jr., Carr, T. J., Chandler, A.C., III, Hyland, L., Fakhoury, S. A., Magaard, V. W., Moore, M. L., strickler, J. E., Debouck, C., and Meek, T. D. (1989). Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors. Proc. Natl. Acad. Sci. USA 86,9752–9756.
18. Dunn, J. G., Stammers, D. K., Harris, C. J., Arrowsmith, R. J., Davies, D. E., Hardy, G. W., and Morton, J. A. (1986). Human renin: a new class of inhibitors. Biochem. Biophys. Res. Commun. 134,71–77.
19. Eberle, J., Bechowsky, B.F. Rose, D., Hauser, U., von der Helm, K., Gürtler, L., and Nitschko, H. (1995). Resistance of HIV type 1 to protease inhibitor Ro 31–8959? AIDS Res. Hum. Retroviruses 77,671–676.
20. Erickson, J., Neidhart, D. J., VanDrie, J., Kempt, D. J., Wang, X. C., Norbeck, D.W., Plattner, J. J., Rittenhouse, J. W., Turon, M., Wideburg, N., Kohlbrenner, W. E., Simmer, R., Helfrich, R., Paul, D. A., and Knigge, M. (1990). Design, activity, and 2?8 crystal structure of a c2 symmetric inhibitor complexed to HIV-1 protease. Science 249,527–533.
21. Erickson-Viitanen, S., Klabe, R. M., Cawood, P. G., O'Neal, P. L., and Meek, J. L. (1994). Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptIde cyclic urea, DMP 323. Antimicrob. Agents Chemother. 38, 1628–1634.
22. Farmerie, W. G., Loeb, D. D., Casavant, C. A., Hutchison, C. A., III, Edgell, M. H., and Swanstrom, R. (1987). Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. Science 236, 305–308.
23. Giam, C. Z., and Boros, I. (1988). In vivo and in vitro autoprocessing of human immunodeficiency virus protease expressed in Escherichia coli. J. Biol. Chem. 263,14617–14620.
24. Graves, M. C., Lim, J. J., Heimer, P., and Kramer, R. (1988). An 11 -kDa form of human immunodeficiency virus protease expressed in coli sufficient for enzymatic activity. Proc. Natl. Acad. Sci. USA 85,2449–2453.
25. Graves, M. C., Meidel, M. C., Pan, Y. C. E., Manneberg, M., Lahm, H. W., and Grüninger-Leitch, F. (1990). Identification of a human immunodeficiency virus-1 protease cleavage site within the 66000 dalton subunit of reverse transcriptase. Biochem. Biophys. Res. Commun. 168,30–36.
26. Greenlee, W. J. (1990). Renin inhibitors. Med. Res. Rev. 10,173–236.
27. Grobelny, D., Wondrak, E. M., Galardy, R. E., and Oroszlan, S. (1990). Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. Biochem. Biophys. Res. Commun. 769,1111–1116.
28. Hallenberger, S., Bosch, V., Angliker, H., Shaw, E., Klenk, H. D., and Garten, W. (1992). Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360,358–361.
29. Hodge, C. N., Aldrich, P. E., Bacheier, L. T., Chang, C. H., Eyermann, C. J., Garber, S., Grubb, M., Jackson, D. A., Jadhav, P. K., Korant, B., Lam, P. Y. S., Maurin, M. B., Meek, J. L., Otto, M. J., Rayner, M. M., Reid, C., Sharpe, T. R., Shum, L., Winslow, D. L., and Erickson-Viitanen, S. (1996). Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chemistry & Biology 3,301–314.
30. Homma, M. (1971). Trypsin action on the growth of Sendai virus in tissue culture cells. I. Restoration of the infectivity for L cells by direct action of trypsin on Lcell-borne Sendai virus. J. Virol., 619.
31. Ivanoff, L. A., Towatari, T., Ray, J., Korant, B. D., Petteway, S. R., Jr. (1986). Expression and site-specific mutagenesis of the poliovirus 3C protease in E. coli. Proc. Natl. Acad. Sci. USA 83, 5392–5396.
32. Jacobson, M. A., De Gruttola, V., Reddy, M., Arduino, J. M., Strickland, S., Reichman, R. C., Bartlett, J. A., Phair, J. P., Hirsch, M. S., Collier, A.C., Soeiro, R., and Volberding, P. (1995). The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS 9, 727–734.
33. Kaplan, A. H., Manchester, M., and Swanstrom, R. (1994). The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68,6782–6786.
34. Katoh, I. T., Yasunaga, Y., Ikawa, Y., and Yoshinaka, Y. (1987) Inhibition of retroviral protease activity by an aspartyl protease inhibitor. Nature 329,654–656.
35. Kempf, D. J., Norbeck, D.W., Codacovi, L., Wang, X. C., Kohlbrenner, W. E., Wideburg, N. E., Paul, D.A., Knigge, M. F., Vasavanonda, S., Craig-Kennard, A., Saldivar, A., Rosenbrook, W., Jr., Clement, J. J., Plattner, J. J., and Erickson, J. (1990). Structure-based, c2 symmetric Inhibitors of HIV protease. J. Med. Chem 33,2687–2689.
36. Kempf, D. J., Codacovi, L., Wang, X. C., Kohlbrenner, W. E., Wideburg, N. E., Saldivar, A., Vasavanonda, S., Marsh, K. C., Bryant, P., Sham, H. L., Green, B. E., Betebenner, D. A., Erickson, J., and Norbeck, D.W. (1993). Symmetry-based inhibitors of HIV protease, structure-activity studies of acylated 2,4-diamino-l,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J. Med. Chem. 36,320–330.
37. Kempt, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., Kong, X. R., Wideburg, N. E., Saldivar, A., Ruiz, L., Kati, W. M., Sham, H.L.M. Robins, T., Stewart, K. D., Hsu, A., Plattner, J. J., Leonard, J. M., and Norbeck, D.W. (1995). ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92,2484–2488.
38. Kido, H., Kamoshita, K., Fukutomi, A., and Katunuma, N. (1993). Processing protease for gp160 human immunodeficiency virus type I envelope glycoprotein precursor in human T4+ lymphocytes. Purification and characterization. J. Biol. Chem. 268,13406–13413.
39. Kisselev, A. (1995). Substrate specificity of retrovirus proteinases. Ph. D. Thesis., University of Moscow.
40. Kohl, N. E., Emini, E. Schleif, W. A., Davis, J., Heimbach, J. C., Dixon, R. A. F., Scolnick, E. M., and Sigal, L.S. (1988). Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 5,4686–4690.
41. Korant, B. D. (1972). Cleavage of viral precursor proteins in vivo and in vitro. J. Virol. 70,751.
42. Korant, B. D. (1979). Virus-specific protease in poliovirus-infected HeLacells. Proc. Natl. Acad. Sci. USA 76,2992–2996.
43. Kotier, M., Arad, G., and Hughes, S. H. (1992). Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active. J. Virol. 66,6781–6783.
44. Kramer, R. A., Schaber, M. D., Skalka, A. M., Ganguly, K., Wong-staal, F., and Reddy, E. P. (1986). HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 231, 1580–1584.
45. Kräusslich, H. G., and Wimmer, E. (1988). Viral proteinases. Annu. Rev. Biochem. 57,71 754.
46. Kräusslich, H. G. (1991). Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 88,3213–3217.
47. Kuo, L. C., and Shafer, J. A., ed. (1994). Retroviral Proteases. Methods in Enzymology, Vol. 241 (New York: Academic Press).
48. Lam, P. Y. S., Jadhav, P. K., Eyermann, C. J., Hodge, C. N., Ru, Y., Bacheler, L. T., Meek, J. L., Otto, M. J., Rayner, M. M., Wong, Y. N., Chang, C. W., Weber, P.C., Jackson, D. A., Sharpe, T. R., and Erickson-Viitanen, S. (1994). Rational desing of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263,380–384.
49. Lindhofer, H., Nitschko, H., Wachinger, G., and von der Helm, K. (1993). HIV protease in HIV-infected cell culture: dual intracellular effects in absence and presence of inhibitor. In: Proteolysis and Protein Turnover, J.s. Bond and A. J. Barrett, eds. (London: Portland Press), pp. 219–224.
50. Lindhofer, H., von der Helm, K., and Nitschko, H. (1995). In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-Lymphocytes. Virology 214,624–627.
51. Loeb, D. D., Hutchison, C. A., III, Edgell, M. H., Farmerie, W. G., and Swanstrom, R. (1989). Mutational analysis of human immuno-dificiency virus type 1 protease suggests functional homology with aspartic proteinases. J. Virol. 63,111–121.
52. McQuade, T. J., Tomasseli, A. G., Liu, L., Karacostas, V., Moss, B., Sawyer, T. K., Heinrikson, R. L., and Tarpley, W. G. (1990). A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247,454–456.
53. Meek, T. D., Dayton, B. D., Metcalf, B.W., Dreyer, G. B., strickler, J. E., Gorniak, J. G., Rosenberg, M., Moore, M. L., Magaard, V. W., and Debouck, C. (1989). Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. Proc. Natl. Acad. Sci. USA 86, 1841–1845.
54. Meek, T. D., Lambert, D. M., Dreyer, G. B., Carr, T. J., Tomaszek, T. A., Jr., Moore, M. L., strickler, J. E., Debouck, C., Hyland, L. J., Matthews, T. J., Metcalf, B. W., and Petteway, S. R. (1990). Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature 343,90–92.
55. Mellor, J.W. (1996). Closing in on human immunodeficiency virus-1 ; antiretroviral therapy back on track with HIV-1 protease inhibitors. Nature Medicine 2, 274–275.
56. Merrill, D. P., Moonis, M., Chou, T. C., and Hirsch, M. S. (1996). Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J. Infect. Dis. 173,355–364.
57. Miller, M., Jaskólski, M., Mohana Rao, J. K., Leis, J., and Wlodawer, A. (1989). Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 337,576–579.
58. Nitschko, H., Lindhofer, H., Eberle, J., Deby, G., Kranz, B., and von der Helm, K. (1994). Long term treatment of HIV infected cell culture with inhibitor Ro 31–8959 leads to complete cure of cells. Antiviral Chemistry & Chemotherapy 5,236–242.
59. Noble, S., and Faulds, D. (1996). Saquinavir A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52,93–112.
60. Oroszlan, S., and Luftig, R. B. (1990). Retroviral proteinases. Curr. Top. Microbiol. and Immunol. 157,153–185.
61. Oswald, M., and von der Helm, K. (1991). Fibronectin is a nonviral substrate for the HIV protease FEBS Lett. 292,298–300.
62. Palmenberg, A.C., Pallansch, M. A., and Rueckert, R. R. (1979). Protease required for processing picornaviral coat protein resides in the viral replicate gene. J. Virol. 32,770–778.
63. Partaledis, J. A., Yamaguchi, K., Tisdale, M., Blair, E. E., Falcione, C., Maschera, B., Myers, R. E., Pazhanisamy, S., Filter, O., Cullinan, A. B., Stuver, C., Byrn, R. A., and Livingston, D. J. (1995). In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease J. Virol. 69,5228–5235.
64. Pearl, L. H., and Taylor, W. R. (1987). A structural model for the retroviral proteases. Nature 329,351–354.
65. Pelham, H. R. B. (1979). Synthesis and proteolytic processing of cowpea mosaic vims proteins in reticulocyte lysates, virology 96,463–477.
66. Pennisi, E., and Cohen, J. (1996). Eradicating HIV from a patient. Science 272,1884.
67. Popovic, M., Sarngadharan, M. G., Read, E., and Galio, R.C. (1984). Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224,497–500.
68. Phylip, L. H., Mills, J.S. Parten, B. F., Dunn, B. M. and Kay, J. (1992)? Intrinsic activity of precursor forms of HIV-1 protease. FEBS Lett. 374,449–454.
69. Roberts, N. A. (1995)? Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 9 Suppl. 2, S27-S32.
70. Richman, D. D. (1996). HIV Therapeutics. Science 272, 1876–1888.
71. Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. B., Galpin, S. A., Handa, B. K., Kay, J., Kröhn, A., Lambert, R. W., Merrett, J. H., Mills, J. S., Parkes, K. E. B., Redshaw, S., Ritchie, A. J., Taylor, D. L., Thomas, G. J., and Machin, P. J. (1990). Rational design of peptide-based HIV protease inhibitors. Science 248,358–361.
72. Schätzl, H., Gelderblom, H. R., Nitschko, H., and von der Helm, K. (1991). Analysis of non-infectious HIV particles produced in presence of HIV protease inhibitor. Arch. Virol. 120,71–81.
73. Scheid, A., and Choppin, P. (1974). Identification of biological activities of paramyxovirus glycoprotein. Activation of cell fusion, hemolysis, and infectivity by proteolytic cleavage of an inactive precursor protein of Sendai virus. Virology 57,475.
74. Schneider, J., and Kent, S. B. H. (1988). Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease Cell 54,363–368.
75. Seelmeier, S., Schmidt, H., Turk, V. J. and von der Helm, K. (1988)? Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA 85,6612–6616.
76. Shoeman, R. L., Höner, B., stoller, T. J., Kesselmeier, C., Miedel, M. C., Traub, P., and Graves, M.C. (1990). Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Natl. Acad. Sci. USA 87,6336–6340.
77. Shoeman, R. L., Kesselmeier, C., Mothes, E., and Höner, B. (1991). Non-viral cellular substrates for human immunodeficiency virus type 1 protease. FEBS Lett. 278,199–203.
78. Shoeman, R. L., Höner, B., Mothes, E.F. and Traub, P. (1992). Potential role of the viral protease in human immunodeficiency virus type 1 associated pathogenesis. Med. Hypotheses 37, 137–150.
79. Strickler, J. E., Gorniak, J., Dayton, B., Meek, T., Moore, M., Magaard, V., Malinowski, J., and Debouck, C. (1989). Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli. Proteins 6,139–154.
80. Thaisrivongs, S., Tomasselli, A. G., Moon, J. B., Hui, J., McQuade, T. J., Turner, S. R., Strohbach, J. W., Howe, W. J., Tarpley, W. G., and Heinrikson, R. L. (1991). Inhibitors of the protease from human immunodeficiency virus: Design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity. J. Med. Chem. 34,2344–2356.
81. Thaisrivongs, S., Tomich, P. K., Watenpaugh, K. D., Chong, K. T., Howe, W. J., Yang, C. P., Strohbach, J. W., Turner, S. R., McGrath, J. P., Bohanon, M. J., Lynn, J. C., Mulichak, A. M., Spinelli, P. A., Hinshaw, R. R., Pagano, P. J., Moon, J. B., Ruwart, M. J., Wilkinson, K. R., Rush, B. D., Zipp, G. L., Dalga, R. J., Schwende, F. J., Howard, G. M., and Padbury, G. E. (1994). Structure-based design of HIV protease inhibitors: 4-hydroxy-coumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chem. 37,3200–3204.
82. Toh, H., Ono, M., Saigo, K., and Miyata, T. (1985). Retroviral protease-like sequence in the yeast transposon Ty1. Nature 375, 691–692?.
83. Tomasselli, A. G., Hui, J. O., Sawyer, T. K., Staples, D. J., Bannow, A., Reardon, I. M., Chaudhary, V. K., Fryling, C. M., Pastan, I., FitzGerald, D. J., and Heinrikson, R. L. (1990). Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates. J. Virol. 64,3157–3161.
84. Vacca, J. P., Guare, J. R., DeSolms, S. J., Sanders, W. M., Giuliani, E. A., Young, S. D., Darke, P. L., Zugay, J., Sgal, I. S., Schleif, W. A., Quintero, J. C., Emini, E. A., Anderson, P. S., and Huff, J. R. (1991). L-687.908, a potent hydroxyethylen-containing HIV protease inhibitor. J. Med. Chem. 34,1228–1230.
85. Vacca, J. P., Dorsey, B. D., Schleif, W. A., Levin, R. B., McDaniel, S. L., Darke, P. L., Zugay, J., Quintero, J. C., Blahy, O. M., Roth, E., Sardana, V. V., Schlabach, A. J., Graham, R.L., Condra, J. H., Gotlib, L., Holloway, M. K., Lm, J., Chen, I. W., Vastag, K., Ostovic, D., Anderson, P. S., Emini, E. A., and Huff, J. R. (1994). L-735,524.? An orally bioavallable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91, 4096–4100.
86. Velia, S. (1995). Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. J. Acquir. Immune Defic. Syndr. Hum. Retroviral. 10 Suppl. 1, S58-S61.
87. Velia, S. (1995). Clinical experience with saquinavir. AIDS 9 Suppl. 2, S21-S25.
88. von der Helm, K. (1977). Cleavage of Rous sarcoma virus polypeptide precursor into internal structural proteins /n wto involves viralprotein p15. Proc. Natl. Acad. Sci. USA 74,911–915.
89. von der Helm, K., and Konze-Thomas, B. (1981). Inhibition of viral maturation and assembley by blocking the precursor processing - a project des.ign. In: Antiviral Chemotherapy (New York: Academic Press), pp. 49–59.
90. von der Helm, K., Gürtler, L., Eberle, J., and Deinhardt, F. (1989). Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A. FEBS Lett. 247,349–352.
91. von der Helm, K., Seelmeier, S., Kisselev, A., and Nitschko, H. (1994). Identification, purification, and cell culture assays of retroviral proteases. Methods Enzymol. 247,89–104.
92. Weber, I. T. (1989). structural alignment of retroviral protease sequences. Gene 85,565–566.
93. Weiss, R. A. (1996). HIV-receptors and the pathogeneis of AIDS. Science 272,1885–1886.
94. West, M. L., and Fairlie, D. P. (1995). Targeting HIV-1 protease: A test of drug-design methodologies. Trends Pharmacol. Sci. 16, 67–75.
95. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B. K., Baldwin, E., Weber, I. T., Selk, L., Clawson, L., Schneider, J., and Kent, S. B. H. (1989). Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616–621.
96. Wlodawer, A., and Erickson, J. W. (1993)? Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62,543–585.
97. Yoshinaka, Y., and Luftig, R. B. (1977). Properties of a p70 proteolytic factor of murine leukemia viruses. Cell 12,709–719.
98. Zybarth, G., and Carter, C. (1995). Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Fol influence PR autoprocessing. J. Virol. 69,3878–3884.